Presently, the confirmatory diagnosis for COVID-19 is by reverse transcription polymerase chain reaction (RT-PCR), which typically takes several hours and requires a molecular laboratory to perform. Also, the limited availability of COVID-19 testing for communities far away from central laboratories, the need for mobile laboratories and point of care (POC) solutions becomes pertinent. Consequently, the combination of equipment and testing protocol with a reduced workflow duration is needed.
MyGo mini from Demyhealth is a portable real time PCR platform that is lightweight at less than 2 kg. It can perform up to 16 reactions using standard 0.1 mL clear qPCR tubes with 10 to 100 μL reaction volume each. The portability of this PCR platform makes it suitable as a point of care solution and can be easily transported in a mobile molecular laboratory.
Using MyGo mini PCR, a direct-PCR protocol for SARS-CoV-2 testing which eliminates the need for RNA extraction was recently documented. This method made use of respiratory samples such as sputum and nasal exudate to test for SARS-CoV-2 in the presence of PCR-inhibitor resistant enzyme; without the need for RNA extraction step after sample collection.
It was discovered that using Mygo mini the work flow for SARS-CoV-2 testing can be reduced to 38 minutes with a limit of detection (LOD) as low as 6 RNA copies per reaction of viral nucleocapsid (N) gene.
Read article for more details: